

RHINOMED ‘MUTE’ NASAL DILATOR TECHNOLOGY PATENT GRANTED IN THE US.

8 August 2023: Melbourne, Australia.

Rhinomed Limited (ASX:RNO OTCQB:RHNMF), (**Rhinomed** or **Company**) a leader in wearable nasal and respiratory technology is pleased to announce that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for patent number 15/319,940. This patent relates to the company's leading Mute nasal dilator technology. This application was filed in December 2016.

The patent titled "Nasal Dilator Devices" predominantly covers the Mute medical device. The Patent provides further protection to Rhinomed's substantial family of medical devices which deliver improved sleep, less snoring and better breathing during sleep and aerobic activity. The granted Patent provides intellectual property protection for our award winning Mute technology in the world's largest consumer health market, the USA, and confirms Rhinomed's technical leadership in the global wearable nasal technology and medical device market.

In the USA Mute is currently sold through America's leading drug store and grocery chains including Walgreens, CVS, Rite Aid, Ingles Markets and online through Amazon. In addition, Mute is available in the UK's leading pharmacy chain Boots and through over 4,000 leading pharmacies in Australia including the Terry White, Chemist Warehouse and Priceline chains.

Rhinomed has built out an extensive intellectual property position in the global nasal dilator, diagnostics, and drug delivery markets. The company has expanded this portfolio more recently to include the revolutionary new Rhinoswab family that standardises the sample collection process while radically improving the user experience.

This granted 'Mute' Patent is part of the approximately 250 Patents and Trademarks both awarded and pending, that form part of our suite of Intellectual Property. These cover our key markets of the USA, Australia, and Europe, and also provide protection including specific markets in South America and Asia.

This report has been authorised for release to the market by the Board.

Company	Investor and Media Relations
Michael Johnson, CEO & Director +61 (0) 3 8416 0900 mjohnson@rhinomed.global Follow us on Twitter @rhinomedceo	Rudi Michelson Monsoon Communications +61(0) 411 402 737 rudim@monsoon.com.au

About Rhinomed Limited (ASX: RNO, OTCQB:RHNMF)

Rhinomed Limited is a Melbourne, Australia based ASX listed nasal and airway technology company that has developed an innovative nasal technology platform that can improve air flow and provide both drug delivery and diagnostic capabilities.